Interní Med. 2017; 19(5): 274-278 | DOI: 10.36290/int.2017.060

Differential diagnosis of monoclonal gammopathies from the point of clinical practice
I. Malignant monoclonal gammopathies

prof. MUDr. Vlastimil Ščudla, CSc.1,2, doc. MUDr. Mgr. Jiří Minařík, Ph.D.2, MUDr. Tomáš Pika, Ph.D.2, doc. MUDr. Jaroslav Bačovský, CSc.2
1 III. interní klinika – nefrologická, revmatologická a endokrinologická, Fakultní nemocnice Olomouc
2 Hemato-onkologická klinika FN a LF UP v Olomouci

Monoclonal gammopathies (MG) are a very heterogeneous group of malignant and non-malignant conditions, that are characterizedby the presence of monoclonal immunoglobulin (MIg, „paraprotein“) or its structural components in serum and/or urine. Thepresented paper shows contemporary classification of MG, list of standard as well as specialized examination methods, and an effectivedifferential diagnosis for an early recognition of malignant MG requiring therapy. The manuscript contains also the overviewof contemporary algorithms for assessment, and sets of diagnostic criteria of the most frequent malignant MG for routine practice.

Keywords: monoclonal gammopathy, multiple myeloma, Waldenström macroglobulinemia, solitary plasmacytoma, plasma cell
leukemia, POEMS syndrome, differential diagnosis

Received: October 30, 2017; Accepted: November 8, 2017; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ščudla V, Minařík J, Pika T, Bačovský J. Differential diagnosis of monoclonal gammopathies from the point of clinical practice
I. Malignant monoclonal gammopathies. Interní Med. 2017;19(5):274-278. doi: 10.36290/int.2017.060.
Download citation

References

  1. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspective risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127. Go to original source...
  2. Hájek R, Adam Z, Ščudla V, et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou. Transf Hematol dnes 2012; 18: 6-89.
  3. Rajkumar SV, Dimopoulos MA, Blade J, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: 538-548. Go to original source...
  4. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Amer Fam Physician 2017; 95: 373-383.
  5. Adam Z. Diferenciální diagnostika monoklonálních gamapatií. Inter Med pro praxi 2004; 5: 279-283.
  6. BMJ Best Practice 2016. Multiple myeloma-Differential diagnosis. http://www.bestpractice.bmj.com/best-practice/monograph/179/diagnosis/differential.html. Získáno 23. 3. 2017.
  7. Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Amer Soc Clin Oncol Educ Book 2016; 35: 418-423. Go to original source...
  8. Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma related bone disease: a systematic review. Brit J Haematol 2013; 162: 50-61. Go to original source... Go to PubMed...
  9. International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. http://imwg.myeloma.org/international-myeloma-working-group-imwg-criteria-for-the... Získáno 23. 3. 2017.
  10. Van De Donk NW, Mutis T, Poddighe PJ, et al. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Inter J Lab Hematol 2016; doi:10.1111/ijlh.12504. Go to original source...
  11. Kyle RA, Larson DR, Therneau TM et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective study. Lancet Haematol 2014; 1: e28-36. Go to original source... Go to PubMed...
  12. Landgren O, Kyle RA, Pfeifer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417. Go to original source...
  13. Hill QA, Rawstron AC, de Tute RM, et al. Outcome prediction in solitary plasmacytoma of bone: a risk stratification model utilizing bone marrow flow cytometry and light chain analysis. Blood 2014; 124: 1296-1299. Go to original source...
  14. De Larrea CR, Kyle RA, Durie BGM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria, and treatment recommendations by the International Myeloma Working Group (IMWG). Leukemia 2013; 27: 780-791. Go to original source... Go to PubMed...
  15. Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk stratification, and management. Amer J Hematol 2014; 89: 214-223. Go to original source... Go to PubMed...
  16. Dispenzieri A, Buadi F. A review of POEMS syndrome. Cancer network 2013; www.cancernetwork.com.
  17. Rajkumar SV, Kyle RA, Connor RF. The heavy chain diseases. UpToDate 2017, www.uptodate.com.
  18. Bianchi G, Anderson KC, Harris NL, et al. The heavy chain diseases: clinical and pathologic features. Oncology 2014; 28: 45-53. Go to PubMed...
  19. Gertz MA. Waldenström macroglobulinemia 2017 update on diagnosis, risk stratification, and management. Amer J Hematol 2017; 92: 209-217. Go to original source... Go to PubMed...
  20. Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and mana-g ement of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85: 824-833. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.